louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05205187: Gut Microbiota and Metabonomics
Official title: Multi-center and Multi-omics Mechanism Research of Gut Microbiota and Metabonomics in Borrmann Type IV Gastric Cancer
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Stomach Neoplasms
Gut Microbiota
Metabolomics
Lead sponsor: First Hospital of China Medical University
Sponsor class: OTHER
Collaborators: name: Liaoning Cancer Hospital & Institute
name: The Second Hospital of Shandong University
name: The General Hospital of Fushun Mining Bureau
name: The fourth People's Hospital of Changzhou
name: The First People's Hospital of Jingzhou
First posted: 2022-01-25
Enrollment: 450
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy population will be selected from community samples. Non-Borrmann IV and Borrmann IV patients will be selected from Department of Oncology in hospitals.

Brief summary: To evaluate the correlation between gut microbiota and metabolites in Borrmann type IV gastric cancer; To find the effects of microflora and metabolites on target organs; To detect the mechanism of key flora and metabolite by in vitro and in vivo experiments; To construct models of gut microbiota and metabonomics by machine learning.


Eligibility criteria: Inclusion Criteria:

1. Patients who sign informed consent.
2. Borrmann classification of gastric cancer is determined by more than 2 pathologists.
3. Patients with BMI 24-28.
4. Karnofsky (KPS) score \>80.

Exclusion Criteria:

1. Patients who take any aspirin, antibiotics, prebiotics, or probiotics within 4 weeks and steroids or immunosuppressants within 6 months prior to specimen collection.
2. Patients who complicate with other malignant tumors.
3. Patients who complicate with diabetes, hypertension, heart disease and infectious diseases.
4. Patients who complicate with inflammatory bowel disease or irritable bowel syndrome.
5. Patients with metastasis.

Primary outcomes:
measure: Participants' characteristics
timeFrame: 1 day
measure: Microbial community structure
timeFrame: 1 day
measure: Metabolite composition
timeFrame: 1 day
measure: Microbes-metabolites correlations
timeFrame: 1 day
measure: Response of target organ
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Changzhou
country: China
facility: The fourth People's Hospital of Changzhou
state: Jiangsu
city: Chaoyang
country: China
facility: Chaoyang Central Hospital
state: Liaoning
city: Fushun
country: China
facility: The General Hospital of Fushun Mining Bureau
state: Liaoning
city: Jinzhou
country: China
facility: First Hospital of Jinzhou Medical University
state: Liaoning
city: Shenyang
country: China
facility: The First Affiliated Hospital of China Medical University
state: Liaoning
city: Ji'nan
country: China
facility: The Second Hospital of Shandong University
state: Shandong
Study officials:
affiliation: First Hospital of China Medical University
name: Kai Li, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06767787: Morbid Obesity and Severe Knee Osteoarthritis - Which Should Be Treated First?
Official title: Morbid Obesity and Severe Knee Osteoarthritis - Which Should Be Treated First? A Randomized Cross-over Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Osteoarthritis of Knee
Arthroplasties, Knee Replacement
Sleeve Gastrectomy
Keywords: knee osteoarthritis
bariatric surgery
laparoscopic sleeve gastrectomy
knee replacement
knee arthroplasty
obesity
Lead sponsor: Memorial University of Newfoundland
Sponsor class: OTHER
First posted: 2025-01-10
Enrollment: 142
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The goal of this study is to determine whether undergoing bariatric surgery before knee replacement leads to better outcomes compared to undergoing knee replacement before bariatric surgery. Our secondary goal is to compare complication rates between these groups to determine if there is a difference based on the order of the two procedures.

Participants will be randomly placed in one of two groups, with each undergoing both procedures but in opposite order. Quality of life will be assessed via questionnaires before and between each procedure, and rates of complications will also be documented to compare their rates between groups.


Eligibility criteria: Inclusion Criteria:

* BMI \> or = 35, on surgical waitlist for a total knee arthroplasty and laparoscopic sleeve gastrectomy

Exclusion Criteria:

* a history of revision surgery, surgery for neoplastic disease, significant mental illness, ASA class \> 3 denoting absence of significant impact of comorbidities, and previous esophagogastric surgery.

Primary outcomes:
measure: SF-36 Physical Function Component Score
timeFrame: At baseline/enrollment followed by a year following each procedure.
Secondary outcomes:
measure: SF-36 Mental Component Score
timeFrame: At baseline/enrolment followed by a year after each procedure
measure: Knee Osteoarthritis Outcome Score (KOOS)
timeFrame: At baseline/enrolment in addition to a year following each procedure
measure: Post-Operative Outcomes
timeFrame: At 12 and 24 months following each intervention
measure: Post-Operative Complications
timeFrame: Surveilled every 3 months post- each procedure, until the 12-month postoperative mark.
Other outcomes:
Locations:
city: St. John's
country: Canada
facility: Health Sciences Centre
state: Newfoundland and Labrador
city: St. John's
country: Canada
facility: St. Clare's Mercy Hospital
state: Newfoundland and Labrador
Study officials:
References:
Clinical trial NCT05570487: RESECTED LYMPH NODES AND SURVIVAL OF PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA: AN OBSERVATIONAL STUDY
Official title: Increasing the Number of Resected Lymph Nodes Improves Overall Survival of Patients With Esophageal Squamous Cell Carcinoma With Positive Lymph Nodes: a Retrospective Analysis of 1656 Cases at a Single Cancer Center
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: the Records of Esophageal Cancer
Keywords: esophageal cancer
lympha nodes
Lead sponsor: Sichuan Cancer Hospital and Research Institute
Sponsor class: OTHER
First posted: 2022-10-06
Enrollment: 1600
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with esophageal cancer and need surgical treatment.

Brief summary: To clarify the effect of the number of lymph node dissection and the number of stations on survival


Eligibility criteria: Inclusion Criteria:

1. Men and women aged 18-85;
2. Histologically confirmed primary thoracic esophageal squamous cell carcinoma,
3. Staging PT1-4A, N0-3, M0 AJCC eighth edition;
4. Excluding lymph node dissection \< 15,(meeting the guideline criteria)

Exclusion Criteria:

1. Patients with a history of previous thoracic and abdominal surgery that may affect lymphatic reflux
2. Patients with distant metastasis confirmed by imaging;
3. Patients with obvious surgical contraindications.

Primary outcomes:
measure: The number of lymph nodes
timeFrame: 2010.1.1-2017.12.30
Secondary outcomes:
Other outcomes:
Locations:
city: Chendu
country: China
facility: Sichuan Cancer Hospital
state: Sichuan
Study officials:
References:
Clinical trial NCT00542087: Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED)
Official title: A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Etoricoxib 60 mg and Diclofenac Sodium 150 mg in Patient With Osteoarthritis of the Knee or Hip
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Osteoarthritis
Lead sponsor: Organon and Co
Sponsor class: INDUSTRY
First posted: 2007-10-10
Enrollment: 516
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare the safety and tolerability of etoricoxib and diclofenac sodium in the treatment of osteoarthritis of the knee or hip during a six week period.


Eligibility criteria: Inclusion Criteria:

* Patient is at least 40 years old and diagnosed with osteoarthritis of the knee or hip
* Has a history of treatment with NSAIDs with positive therapeutic benefit
* Agree to limit alcohol intake to less than 7 drinks per week and avoid unusual strenuous activity
* Females who are able to have children must have negative urine pregnancy tests

Exclusion Criteria:

* Has rheumatoid arthritis, lupus, Paget's disease affecting the study joint, or Wilson's disease
* History of acute ligament or meniscus damage to the study joint (knee or hip) within the past 2 years or arthroscopic surgery on the affected study joint with the past 6 months
* Requires joint replacement

Primary outcomes:
measure: This study will assess the effectiveness of the study drug vs. a comparator to treat successfully OA-related joint pain (judged by WOMAC pain subscale).
Secondary outcomes:
measure: The study drug will be safe and well tolerated during the course of the study.
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Zacher J, Feldman D, Gerli R, Scott D, Hou SM, Uebelhart D, Rodger IW, Ozturk ZE; etoricoxib OA study group. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin. 2003;19(8):725-36. doi: 10.1185/030079903125002469.
Clinical trial NCT00380887: Study Comparing Four New Formulations for Premarin in Healthy Postmenopausal Women
Official title: An Open-Label, Single-Dose, Randomized, 4-Period, Partial Crossover Bioequivalence/Bioavailability Study Among Four New Formulations of Premarin 0.45 mg/Medroxyprogesterone Acetate (MPA) 1.5 mg Compared With a Reference Formulation of Premarin/MPA (Prempro) 0.45 mg/1.5 mg in Healthy Postmenopausal Women
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Postmenopause
Keywords: bioavailability
bioequivalence
marketed product
Premarin
Medroxyprogesterone acetate
MPA
Postmenopausal
vasomotor symptoms
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2006-09-27
Enrollment: 54
Sex: FEMALE
Minimum age (years): 35
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: The purpose of this study is to determine bioequivalence and bioavailability of four different Premarin/MPA test formulations versus the current formulation for Prempro.


Eligibility criteria: Inclusion Criteria:

1. Healthy postmenopausal women aged 35 to 70 years
2. Nonsmoker or smoker of less than 10 cigarettes per day

Exclusion Criteria:

1. History or presence of clotting disorders
2. History or presence of cancer
3. Presence of HIV, hepatitis B or hepatitis C
4. History of drug or alcohol abuse

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT02237287: Combination of Taliderm® and Vacuum-assisted Closure (VAC) for Treatment of Pressure Ulcers
Official title: Combination of Taliderm® and VAC for Treatment of Pressure Ulcers - a Pilot Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: EARLY_PHASE1
Conditions: Wounds
Pressure Ulcer
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
Collaborators: name: Marine Polymer Technologies, Inc.
First posted: 2014-09-11
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: Background: The wound healing promoting effect of negative wound pressure therapies (NWPT) takes place at the wound foam interface. Implementation of bioactive substances at this site represents a major research area for the development of future NWPT devices.

Methods: Wound healing kinetics of pressure ulcers treated by vacuum assisted closure devices with or without the implementation of a thin interface of poly-N-acetyl glucosamine nanofibers (sNAG) was studied in a prospective randomized clinical trial.


Eligibility criteria: Inclusion Criteria:

* Ischial/sacral Pressure ulcer between 4 and 15cm diameter
* Greater than or equal to 18 years of age
* Ability to obtain informed consent

Exclusion Criteria:

* Connective tissue disorders
* Immunosuppression, Hemodialysis, Steroids
* Pregnancy
* Sepsis

Primary outcomes:
measure: Number of Participants with Adverse Events as a Measure of Safety and Tolerability
timeFrame: up to 1 year
measure: Wound surface area increase, respectively decrease as a measure of the effect of the studied devices on pressure ulcer healing
timeFrame: up to 1 year
Secondary outcomes:
measure: Wound Healing characteristics
timeFrame: up to 1 year
measure: Wound Healing characteristics
timeFrame: up to 1 year
measure: Wound Healing characteristics
timeFrame: up to 1 year
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: University Hospital Basel
city: Nottwil
country: Switzerland
facility: Swiss Paraplegic Centre Nottwil
Study officials:
affiliation: University Hospital, Basel, Switzerland
name: Dirk J. Schaefer, Prof.Dr.
role: STUDY_DIRECTOR
References:
Clinical trial NCT05647187: Effect Narrow-Band UVB Radiations
Official title: Effect Narrow-Band UVB Radiation Therapy on Suppression of IL 17 Axis in Psoriatic Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Psoriasis Vulgaris
UVB Phototherapy Burn
Keywords: Psoriasis vulgaris
UVB radiations
Interleukin 17
Lead sponsor: South Valley University
Sponsor class: OTHER
First posted: 2022-12-12
Enrollment: 80
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Narrow-band UVR affects Interleukin 17 which has a major role in the pathogenesis of psoriasis Vulgaris. the aim of this study to evaluate the serum levels of Interleukin 17 in psoriatic patients and compare with the levels in healthy controls \& evaluate the effect of narrow-band ultraviolet B (NB-UVB) on the serum of Interleukin 17 and the treatment of psoriasis Vulgaris.

Detailed description: Nowadays Interleukin 17 has a major role in the pathogenesis of psoriasis Vulgaris.

the aim of this study to evaluate the serum levels of Interleukin 17 in psoriatic patients and compare them with the levels in healthy controls \& evaluate the effect of narrow-band ultraviolet B (NB-UVB) on the serum of Interleukin 17 and the treatment of psoriasis Vulgaris. This prospective randomized clinical trial was carried out in Dermatology Department, South Valley University Hospitals included from September 2020 to August 2021, enrolled 40 psoriatic patients and 40 controls. The study was submitted for approval from the Scientific and Ethical Committees and coded as ( SVU.MED.DVA021, Code 1, N 76). Forty patients were treated with NB-UVB by starting the dose from 0.5 mJ/cm2 for all cases (Skin phototypes III or IV). The dosage is subsequently increased by 20 % per session. Sessions were given three times weekly on non-consecutive days for 12 weeks (three months). Serum Interleukin 17 levels were measured pre-and post-12 weeks narrow-band ultraviolet B by performing an enzyme-linked immune sorbent assay (ELISA). Main outcome and Measures: Improvement of psoriasis Severity Index score after 12 weeks narrow- Band UVR treatment and serum-decreased IL17 by performing an enzyme-linked immune sorbent assay (ELISA).

Eligibility criteria: Inclusion Criteria:

* Patients with psoriasis diagnosed clinically

Exclusion Criteria:

* Patient with history of skin cancer. Patient with history of photosensitivity. Patient receiving immune suppressive drugs .

Primary outcomes:
measure: Primary (main):
timeFrame: 12 weeks
Secondary outcomes:
measure: Secondary (subsidiary)
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Qinā
country: Egypt
facility: South Valley University
state: Qena
Study officials:
affiliation: South Valley University
name: Hassan M Ibrahim, professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT01090687: Role of 3D Tomography in Breast Cancer
Official title: Role of 3D Tomography in Breast Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Keywords: breast cancer, CT scans, mammography
Lead sponsor: University of Rochester
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2010-03-22
Enrollment: 150
Sex: FEMALE
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women, age 40 or older, who are scheduled for biopsy after classification as BI-RADS 4/5 and have had a screening or diagnostic full-field digital mammography (FFDM) exam, and who meet the inclusion criteria, are eligible to participate.

Brief summary: The primary aim of this pilot study is to define the role of dedicated cone beam breast computed tomography in breast cancer imaging. This research is a prelude of a more comprehensive clinical trial that may follow.


Eligibility criteria: Inclusion Criteria:

* All women, age 40 or older, who are scheduled for biopsy after classification as BI-RADS 4/5 and have had a screening or diagnostic full-field digital mammography (FFDM) exam are eligible to participate, except for exclusions noted below.
* Able to provide informed consent.

Exclusion Criteria:

* Males
* Women less than 40 years old
* Pregnant women
* Lactating women
* Woman who have had bilateral mastectomies
* Women with physical limitations that may prohibit resting prone on the exam table, such as, but not limited to: frozen shoulder, recent heart surgery, pace maker
* Women who are unable to tolerate study constraints, frail or unable to cooperate
* Women with large breasts that cannot be accommodated within the field of view of the CT system
* Women who have received radiation treatments to the thorax for malignant and nonmalignant conditions, such as (but not limited to)

  * Treatment for enlarged thymus gland as an infant
  * Irradiation for benign breast conditions, including breast inflammation after giving birth
  * Treatment for Hodgkin's disease
* Women who have participated in a prior breast clinical trial that gave additional radiation dose, such as an additional mammogram.
* Women who have received large numbers of diagnostic x-ray examinations for monitoring of disease such as (but not limited to)

  * Tuberculosis
  * Severe scoliosis

Primary outcomes:
measure: Correlation between mammography and breast CT on lesion detection
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: University of Rochester Medical Center, Highland Breast Imaging Center
state: New York
Study officials:
affiliation: University of Massachusetts, Worcester
name: Andrew Karellas, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Massachusetts, Worcester
name: Stephen Glick, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00002087: Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals
Official title: Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: HIV Infections
Keywords: Recombinant Proteins
Acquired Immunodeficiency Syndrome
Antigens, CD4
AIDS-Related Complex
Lead sponsor: NIH AIDS Clinical Trials Information Service
Sponsor class: INDUSTRY
First posted: 2001-08-31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: To investigate the safety and tolerance of an increasing number of infusions per week of alvircept sudotox ( sCD4-PE40; soluble CD4-Pseudomonas exotoxin ) at a fixed dose when administered to HIV-1-infected individuals. To investigate the effect of sCD4-PE40 on the following parameters: T lymphocyte subsets, plasma HIV RNA and cellular HIV proviral DNA in PBMC and CD4 cells, p24 levels, serum beta-2 microglobulin, and neopterin levels.


Eligibility criteria: Inclusion Criteria

Patients must have:

* HIV positivity confirmed by Western blot.
* CD4 count of 100 - 500 cells/mm3 on a morning draw within 3 weeks prior to study entry.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms and conditions are excluded:

* Concurrent neoplasms other than basal cell carcinoma of the skin, in situ carcinoma of the cervix, or nondisseminated Kaposi's sarcoma.
* Hemophilia or other clotting disorders.
* Major organ allograft.
* Significant cardiac, hepatic, renal, or CNS disease.

Prior Medication:

Excluded:

* Antiretroviral agents within 2 months prior to study entry.
* Known anti-HIV medication within 60 days prior to study entry.
* Prior immunomodulators (e.g., systemic steroids, interferons, or interleukins) or other chemotherapy.

Prior Treatment:

Excluded:

* Prior radiation therapy. Active substance abuse.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford Univ Med Ctr
state: California
Study officials:
References:
citation: Davey RT Jr, Boenning CM, Herpin BR, Batts DH, Metcalf JA, Wathen L, Cox SR, Polis MA, Kovacs JA, Falloon J, et al. Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus. J Infect Dis. 1994 Nov;170(5):1180-8. doi: 10.1093/infdis/170.5.1180.
Clinical trial NCT03190187: Spinal Manipulation Effectiveness in Spinal Disorders
Official title: Spinal Manipulation Effectiveness in Pain, Disability and Range of Motion.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Low Back Pain
Cervical Pain
Pain
Lead sponsor: University of Jaén
Sponsor class: OTHER
First posted: 2017-06-16
Enrollment: 98
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Single blind parallel clinical trial
Primary purpose: TREATMENT

Brief summary: The aim of the present intervention study is to determine the effectiveness of manipulation techniques.

Detailed description: Spinal manipulation of the spine will be assessed in patients with musculoskeletal disorders to determine the effects of different manual therapy approaches.

Eligibility criteria: Inclusion Criteria:

* Currently suffering spinal related pain (neck, thoracic or lumbar).
* Not receiving additional treatment for the treated condition.

Exclusion Criteria:

* Presence of red flags such as tumors or infection.
* Recent surgery.
* Fractures.

Primary outcomes:
measure: Visual analogical scale
timeFrame: Change from baseline to 4 weeks and 6 months of follow up.
Secondary outcomes:
measure: Oswestry Disability Index
timeFrame: Change from baseline to 4 weeks and 6 months of follow up.
measure: Range of Motion
timeFrame: Change from baseline to 4 weeks and 6 months of follow up.
Other outcomes:
Locations:
city: Jaen
country: Spain
facility: University of Jaen
Study officials:
affiliation: University of Jaen
name: DAVID Curz DIAZ, PhD
role: PRINCIPAL_INVESTIGATOR
References: